Related references
Note: Only part of the references are listed.Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
Friederike Holze et al.
NEUROPSYCHOPHARMACOLOGY (2020)
Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers
Neiloufar Family et al.
PSYCHOPHARMACOLOGY (2020)
Changes in brain metabolites related to stress resilience: Metabolomic analysis of the hippocampus in a rat model of depression
Hayato Akimoto et al.
BEHAVIOURAL BRAIN RESEARCH (2019)
Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects
Friederike Holze et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers
Anya K. Bershad et al.
BIOLOGICAL PSYCHIATRY (2019)
Motives and Side-Effects of Microdosing With Psychedelics Among Users
Nadia R. P. W. Hutten et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2019)
Microdosing psychedelics: More questions than answers? An overview and suggestions for future research
Kim P. C. Kuypers et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2019)
The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial
Steliana Yanakieva et al.
PSYCHOPHARMACOLOGY (2019)
Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration
James Fadiman et al.
JOURNAL OF PSYCHOACTIVE DRUGS (2019)
Modulation of Serum Brain-Derived Neurotrophic Factor by a Single Dose of Ayahuasca: Observation From a Randomized Controlled Trial
Raissa Nobrega de Almeida et al.
FRONTIERS IN PSYCHOLOGY (2019)
Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD)
David E. Nichols
ACS CHEMICAL NEUROSCIENCE (2018)
Psychedelics Promote Structural and Functional Neural Plasticity
Calvin Ly et al.
CELL REPORTS (2018)
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression
Leor Roseman et al.
FRONTIERS IN PHARMACOLOGY (2018)
Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor
Katrin H. Preller et al.
ELIFE (2018)
Serotonin 2A Receptor Signaling Underlies LSD-induced Alteration of the Neural Response to Dynamic Changes in Music
Frederick S. Barrett et al.
CEREBRAL CORTEX (2018)
Psychedelics as Medicines: An Emerging New Paradigm
D. E. Nichols et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Alterations of consciousness and mystical-type experiences after acute LSD in humans
Matthias E. Liechti et al.
PSYCHOPHARMACOLOGY (2017)
Safety pharmacology of acute MDMA administration in healthy subjects
Patrick Vizeli et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2017)
Modern Clinical Research on LSD
Matthias E. Liechti
NEUROPSYCHOPHARMACOLOGY (2017)
The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future
Robin L. Carhart-Harris et al.
NEUROPSYCHOPHARMACOLOGY (2017)
Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation
Rainer Kraehenmann et al.
PSYCHOPHARMACOLOGY (2017)
Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects
Patrick C. Dolder et al.
CLINICAL PHARMACOKINETICS (2017)
The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation
Katrin H. Preller et al.
CURRENT BIOLOGY (2017)
Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans
Patrick C. Dolder et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2016)
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Roland R. Griffiths et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
Stephen Ross et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality
Patrick C. Dolder et al.
NEUROPSYCHOPHARMACOLOGY (2016)
The paradoxical psychological effects of lysergic acid diethylamide (LSD)
R. L. Carhart-Harris et al.
PSYCHOLOGICAL MEDICINE (2016)
Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects
Yasmin Schmid et al.
BIOLOGICAL PSYCHIATRY (2015)
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Frederick S. Barrett et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression
C. N. Haile et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2014)
Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases
Peter Gasser et al.
JOURNAL OF NERVOUS AND MENTAL DISEASE (2014)
Prediction of Psilocybin Response in Healthy Volunteers
Erich Studerus et al.
PLOS ONE (2012)
Effects of a β-blocker on the cardiovascular response to MDMA (Ecstasy)
C. M. Hysek et al.
EMERGENCY MEDICINE JOURNAL (2010)
Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV)
Erich Studerus et al.
PLOS ONE (2010)
LSD-assisted psychotherapy in persons suffering from anxiety associated with advanced-stage life threatening diseases. A phase-II, double-blind, placebo-controlled dose-response pilot study
Torsten Passie et al.
CNS NEUROSCIENCE & THERAPEUTICS (2008)
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
R. R. Griffiths et al.
PSYCHOPHARMACOLOGY (2006)
Share Paper
